Agency Business briefs

Share this article:
G2 named Paul Velardi its US executive director for health and wellness. Velardi left Euro RSCG Life 4D, where he was president, to join the WPP shop.

Chicago shop Topin & Associates has formed a strategic partnership with Bridgewater, NJ-based Advanced Clinical Concepts, the companies announced. Their “Science Bridge” offering “aims to help clients bridge the gap that often occurs when companies separate their promotional advertising efforts from their promotional scientific and educational programs,” said Al Topin.

Roska Healthcare has rebranded with a new color palette, a shortened name and the launch of its Catalyst Brand Acceptance Model, which “focuses on the psychology of acceptance as the key motivational driver” instead of merely raising brand awareness.

The Alzheimer's Association National Capital Area Chapter named Allison & Partners PR agency of record for a new women's initiative aimed at reaching Alzheimer's patients and caregivers through outreach initiatives and events.

Sanofi tapped Parsippany, NJ-based Natrel Communications to provide oncology payer consulting and support.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?